Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) had its price target increased by equities researchers at Cantor Fitzgerald from $22.00 to $25.00 in a report issued on Friday, The Fly reports. Cantor Fitzgerald’s price target suggests a potential upside of 57.04% from the company’s current price.
Other equities analysts also recently issued research reports about the stock. Piper Sandler upped their price objective on shares of Catalyst Pharmaceuticals from $20.00 to $21.00 in a report on Tuesday, February 7th. HC Wainwright upped their price objective on shares of Catalyst Pharmaceuticals from $18.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, December 21st. StockNews.com assumed coverage on shares of Catalyst Pharmaceuticals in a report on Thursday. They set a “buy” rating on the stock. Finally, Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $18.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, January 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $21.50.
Catalyst Pharmaceuticals Stock Performance
Shares of Catalyst Pharmaceuticals stock opened at $15.92 on Friday. The company has a market capitalization of $1.66 billion, a PE ratio of 21.51 and a beta of 1.16. The company has a 50-day simple moving average of $16.41 and a two-hundred day simple moving average of $15.61. Catalyst Pharmaceuticals has a one year low of $6.15 and a one year high of $22.11.
Institutional Investors Weigh In On Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.
- Get a free copy of the StockNews.com research report on Catalyst Pharmaceuticals (CPRX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.